<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666143</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-900-103</org_study_id>
    <secondary_id>CTR20181404</secondary_id>
    <nct_id>NCT03666143</nct_id>
  </id_info>
  <brief_title>A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.</brief_title>
  <official_title>A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, non-randomized Phase 1b clinical trial for patients with&#xD;
      histologically or cytologically confirmed locally advanced or metastatic tumors including&#xD;
      non-squamous or squamous NSCLC, RCC, OC, or melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive sitravatinib 120 mg orally once daily in combination with&#xD;
      tislelizumab 200 mg IV once every 3 weeks until occurrence of PD, unacceptable toxicity,&#xD;
      death, withdrawal of consent, or study termination by sponsor.&#xD;
&#xD;
      There will be 9 cohorts in the study. Approximately 20 patients will be enrolled into each&#xD;
      cohort. The patients will be enrolled according to their tumor type and prior anti-programmed&#xD;
      cell death protein-1 (PD-1)/PD-L1 antibody treatment.&#xD;
&#xD;
        -  Cohort A: Anti-PD-1/PD-L1 antibody refractory/resistant metastatic, non-squamous NSCLC&#xD;
&#xD;
        -  Cohort B: Anti-PD-1/PD-L1 antibody naïve metastatic, non-squamous NSCLC&#xD;
&#xD;
        -  Cohort C: Anti-PD-1/PD-L1 antibody refractory/resistant metastatic or advanced RCC&#xD;
&#xD;
        -  Cohort D (China-only): Metastatic or advanced RCC without prior systemic therapy&#xD;
&#xD;
        -  Cohort E: Anti-PD-1/PD-L1 antibody naïve recurrent and platinum resistant epithelial OC&#xD;
&#xD;
        -  Cohort F: Anti-PD-1/PD-L1 antibody treated metastatic, squamous NSCLC • Cohort G:&#xD;
           Anti-PD-1/PD-L1 antibody refractory/resistant unresectable or metastatic melanoma&#xD;
&#xD;
        -  Cohort H: PD-L1 positive, aive, advanced or metastatic, non-squamous NSCLC&#xD;
&#xD;
        -  Cohort I: PD-L1 positive,naive, advanced or metastatic, squamous NSCLC&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs) per NCI-CTCAE version 5.0</measure>
    <time_frame>All AEs and SAEs will be reported until either 30 days after last dose of study drug(s) or initiation of new anticancer therapy, whichever occurs first. Immune-related should be reported until 90 days after the last dose of tislelizumab</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Anti-PD-1/PD-L1 antibody refractory/resistant NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-PD-1/PD-L1 antibody naïve NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-PD-1/PD-L1 antibody refractory/resistant RCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic or advanced RCC without prior systemic therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-PD-1/PD-L1 naïve recurrent / platinum resistant OC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-PD-1/PD-L1 treated metastatic, squamous NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-PD-1/PD-L1 antibody R/R melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-L1 positive, naïve, advanced or metastatic, non-sq NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-L1 positive, naïve, advanced or metastatic, sq NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitravatinib</intervention_name>
    <description>Sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks</description>
    <arm_group_label>Anti-PD-1/PD-L1 antibody R/R melanoma</arm_group_label>
    <arm_group_label>Anti-PD-1/PD-L1 antibody naïve NSCLC</arm_group_label>
    <arm_group_label>Anti-PD-1/PD-L1 antibody refractory/resistant NSCLC</arm_group_label>
    <arm_group_label>Anti-PD-1/PD-L1 antibody refractory/resistant RCC</arm_group_label>
    <arm_group_label>Anti-PD-1/PD-L1 naïve recurrent / platinum resistant OC</arm_group_label>
    <arm_group_label>Anti-PD-1/PD-L1 treated metastatic, squamous NSCLC</arm_group_label>
    <arm_group_label>Metastatic or advanced RCC without prior systemic therapy</arm_group_label>
    <arm_group_label>PD-L1 positive, naïve, advanced or metastatic, non-sq NSCLC</arm_group_label>
    <arm_group_label>PD-L1 positive, naïve, advanced or metastatic, sq NSCLC</arm_group_label>
    <other_name>Tislelizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide written informed consent and can understand and agree to comply with&#xD;
             the requirements of the study and the Schedule of Assessments&#xD;
&#xD;
          2. Age ≥ 18 years on the day of signing the informed consent form (or the legal age of&#xD;
             consent in the jurisdiction in which the study is taking place)&#xD;
&#xD;
          3. At least 1 measurable lesion as defined by RECIST v1.1&#xD;
&#xD;
          4. Provide archival tumor tissue (formalin-fixed paraffin-embedded block [FFPE] with&#xD;
             tumor tissue or unstained slides), if available.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1&#xD;
&#xD;
          6. Adequate hematologic and end-organ function&#xD;
&#xD;
          7. Patients with inactive/asymptomatic carrier, chronic, or active hepatitis B virus&#xD;
             (HBV) must have HBV deoxyribonucleic acid (DNA) &lt; 500 IU/mL (or 2500 copies/mL) at&#xD;
             Screening&#xD;
&#xD;
          8. Females of childbearing potential must be willing to use a highly effective method of&#xD;
             birth control for the duration of the study, and ≥ 120 days after the last dose of&#xD;
             study drugs and have a negative serum pregnancy test ≤ 7 days of first dose of study&#xD;
             drugs&#xD;
&#xD;
          9. Non-sterile males must be willing to use a highly effective method of birth control&#xD;
             for the duration of the study and for ≥ 120 days after the last dose of study drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unacceptable toxicity on prior anti-PD-1/PD-L1 treatment.&#xD;
&#xD;
          2. Active leptomeningeal disease or uncontrolled brain metastasis.&#xD;
&#xD;
          3. Active autoimmune diseases or history of autoimmune diseases that may relapse.&#xD;
&#xD;
          4. Any active malignancy ≤ 2 years&#xD;
&#xD;
          5. Any condition that required systemic treatment with either corticosteroids (&gt; 10 mg&#xD;
             daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days&#xD;
             before first dose of study drugs&#xD;
&#xD;
          6. History of interstitial lung disease, noninfectious pneumonitis or uncontrolled&#xD;
             diseases, including pulmonary fibrosis, acute lung diseases, etc.&#xD;
&#xD;
        8. Severe chronic or active infections (including tuberculosis infection, etc.) requiring&#xD;
        systemic antibacterial, antifungal or antiviral therapy, within 14 days prior to first dose&#xD;
        of study drugs&#xD;
&#xD;
        9. Known history of HIV infection&#xD;
&#xD;
        10. Patients with active hepatitis C infection.&#xD;
&#xD;
        11. Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose&#xD;
        of study drugs&#xD;
&#xD;
        12. Prior allogeneic stem cell transplantation or organ transplantation&#xD;
&#xD;
        13. Hypersensitivity to tislelizumab or sitravatinib, to any ingredient in the formulation,&#xD;
        or to any component of the container&#xD;
&#xD;
        14. Bleeding or thrombotic disorders or use of anticoagulants such as warfarin or similar&#xD;
        agents requiring therapeutic INR monitoring within 6 months before first dose of study&#xD;
        drugs&#xD;
&#xD;
        15. Concurrent participation in another therapeutic clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Blacktown Cancer and Haematology Centre</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICON Cancer Foundation</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Limited</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Guo J, Zhou Q, Huang D, Yu X, Zhao J, Chu Q, Ma Z, Millward M, Gao B, Goh J, Markman B, Voskoboynik M, Gan H, Coward J, Chen C, Xiang X, Qui J, Xu Y, Yang L, Wu YL. A phase 1b study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients (pts) with advanced solid tumors. Chinese Society of Clinical Oncology. 2019.</citation>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

